PE/Cy7® Anti-CD45 antibody [MEM-28] (ab239317)
Key features and details
- PE/Cy7® Mouse monoclonal [MEM-28] to CD45
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: PE/Cy7®. Ex: 496nm, Em: 774nm
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
PE/Cy7® Anti-CD45 antibody [MEM-28]
See all CD45 primary antibodies -
Description
PE/Cy7® Mouse monoclonal [MEM-28] to CD45 -
Host species
Mouse -
Conjugation
PE/Cy7®. Ex: 496nm, Em: 774nm -
Specificity
The antibody MEM-28 reacts with an extracellular epitope on all alternative forms of human CD45 antigen (Leukocyte Common Antigen), a 180-220 kDa single chain type I transmembrane protein expressed at high level on all cells of hematopoietic origin, except erythrocytes and platelets. -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human
Does not react with: Horse -
Immunogen
Tissue, cells or virus corresponding to CD45. (Human thymocytes and T lymphocytes).
-
Epitope
Extracellular region. -
Positive control
- Flow Cyt: Human peripheral blood cells.
-
General notes
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.4
Preservative: 0.0975% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Size exclusion -
Purification notes
Purified antibody is conjugated with tandem dye PE/Cy7 ® under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary. -
Clonality
Monoclonal -
Clone number
MEM-28 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
- FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)
- PE Anti-CD45 antibody [MEM-28], prediluted (ab134202)
- PerCP/Cy5.5® Anti-CD45 antibody [MEM-28] (ab157309)
- APC/Cy7® Anti-CD45 antibody [MEM-28] (ab197130)
- PE/DyLight™ 594 Anti-CD45 antibody [MEM-28] (ab223183)
- Alexa Fluor® 647 Anti-CD45 antibody [MEM-28] (ab239276)
- APC Anti-CD45 antibody [MEM-28] (ab28106)
- Biotin Anti-CD45 antibody [MEM-28] (ab28107)
- PerCP Anti-CD45 antibody [MEM-28] (ab65952)
- Anti-CD45 antibody [MEM-28] (ab8216)
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab239317 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use 4µl for 106 cells.
The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
|
Notes |
---|
Flow Cyt
Use 4µl for 106 cells. The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
|
Target
-
Function
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. -
Involvement in disease
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains. -
Domain
The first PTPase domain interacts with SKAP1. -
Post-translational
modificationsHeavily N- and O-glycosylated. -
Cellular localization
Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts. - Information by UniProt
-
Database links
- Entrez Gene: 5788 Human
- Omim: 151460 Human
- SwissProt: P08575 Human
- Unigene: 654514 Human
-
Alternative names
- B220 antibody
- CD 45 antibody
- CD45 antibody
see all
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab239317 has not yet been referenced specifically in any publications.